Aprinoia Therapeutics (Aprinoia Therapeutics) Days Payable : 0.00 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Days Payable?

Aprinoia Therapeutics's average Accounts Payable for the six months ended in Jun. 2023 was $8.10 Mil. Aprinoia Therapeutics's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.00 Mil.

The historical rank and industry rank for Aprinoia Therapeutics's Days Payable or its related term are showing as below:

APRI's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Aprinoia Therapeutics's Days Payable stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

Aprinoia Therapeutics Days Payable Historical Data

The historical data trend for Aprinoia Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Days Payable Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Days Payable

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Days Payable	-	-	-	-

Competitive Comparison of Aprinoia Therapeutics's Days Payable

For the Biotechnology subindustry, Aprinoia Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Days Payable falls into.

Aprinoia Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aprinoia Therapeutics's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0.432	+	8.887)	/	2 )	/	0	*	365
=	4.6595					/	0	*	365
=	N/A

Aprinoia Therapeutics's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (8.887	+	7.318)	/	2 )	/	0	*	365 / 2
=	8.1025					/	0	*	365 / 2
=	N/A

Aprinoia Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines